Research Advance of Venetoclax in Hematological Tumors--Review.
10.19746/j.cnki.issn.1009-2137.2020.04.058
- Author:
Ling-Yun CHEN
1
;
Yong-Ping SONG
2
Author Information
1. Department of Hematology, Cancer Hospital Affiliated to Zhengzhou University，Zhengzhou 450008，Henan Province，China.
2. Department of Hematology, Cancer Hospital Affiliated to Zhengzhou University，Zhengzhou 450008，Henan Province，China. E-mail：songyongping132@163.com.
- Publication Type:Journal Article
- MeSH:
Aged;
Antineoplastic Agents;
therapeutic use;
Bridged Bicyclo Compounds, Heterocyclic;
therapeutic use;
Hematologic Neoplasms;
Humans;
Leukemia, Lymphocytic, Chronic, B-Cell;
drug therapy;
Sulfonamides
- From:
Journal of Experimental Hematology
2020;28(4):1419-1423
- CountryChina
- Language:Chinese
-
Abstract:
Venetoclax is a selective inhibitor of the anti-apoptotic protein B-cell lymphoma 2（BCL-2）and has great potential in treating a variety of hematological tumors. In recent years, domestic and foreign scholars have tried to use venetoclax singal or in combination with some drugs to treat the patients with hematological tumors, including elderly acute myeloid leukemia（AML）patients un suitable for intensive chemotherapy, relapsed or refractory chronic lymphocytic leukemia（CLL）, Non-Hodgkin's lymphoma（NHL）and multiple myeloma（MM）patients, these studies have achieved good results．At the same time，some scholars found that the secondary drug-resistance occurred in some patients who continuous treated with Venetoclax, and explored the Venetoclax-resistant mechanism. In this review, the research advance of Venetoclax in hematological tumors and the mechanisms of drug resistance are summarized and discussed briefly.
